Abstract: The present invention relates to liquid formulations of levothyroxine or a pharmaceutically acceptable salt thereof intended for parenteral administration, wherein the formulations are devoid of tromethamine. In particular, the invention provides a stable ready-to-use liquid formulation of levothyroxine or a pharmaceutically acceptable salt thereof intended for parenteral administration, wherein the formulation is devoid of tromethamine. The formulations prepared by using the current invention exhibit good physical and chemical stability.

Abstract: The present invention relates to an ophthalmic composition comprising from 0.005% to 0.02% bimatoprost by weight and one or more pharmaceutically acceptable excipient, wherein said composition is free of benzalkonium chloride. The invention also relates to bimatoprost ophthalmic compositions comprising one or more penetration enhancers other than benzalkonium chloride. Further, the invention also provides a process of preparing such compositions and their use for lowering intraocular pressure and treating glaucoma.

Abstract: Disclosed herein are new compositions comprising (1) an antibacterial component comprising (a) a complex comprising (i) an active pharmaceutical ingredient (API) wherein the active pharmaceutical ingredient is tobramycin, a similar compound, or a derivative of either thereof and (ii) a complexing agent, or (b) a derivative of tobramycin or a similar compound comprising one or more conjugates/derivatizing groups, wherein the complexing agent or conjugate(s) cause a detectable increase in API permeation of corneal cells, retention in corneal cells, or both, as compared to the non-complexed or non-derivatized API, and (2) an effective amount of an anti-inflammatory agent, such as dexamethasone or another dexamethasone compound. This disclosure also describes new methods of using such compositions, producing such compositions, and the like.

Abstract: Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a loteprednol compound. In aspects, the compositions are stable suspensions, which maintain physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent that provides both functions. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g.

Abstract: The present invention relates to a process for preparation of an insoluble corticosteroid and a soluble corticosteroid composition by moist heat sterilization and homogenization. In particular, the invention relates to a process for the preparation of a sterilized suspension of betamethasone acetate and betamethasone sodium phosphate, wherein the process comprises sterilizing a slurry of the betamethasone acetate by moist heat sterilization or autoclaving in about 30% to about 70% of water to a temperature of about 115° C. to about 128° C. for about 15 minutes to about 60 minutes under nitrogen atmosphere. The suspensions prepared by using the current invention exhibited good physical and chemical stability. Compositions related thereto are also disclosed.

Abstract: Disclosed herein are compositions comprising tobramycin or a tobramycin derivative that exhibit improvements in permeation of corneal cells, retention in corneal cells, or both. Such compositions can comprise tobramycin or tobramycin derivative(s) complexed to an agent which facilitates improved permeation of corneal cells, retention in corneal cells, or both. The invention also relates to a process of preparing such compositions.

Abstract: The invention relates to formulations and compositions comprising one or more glycopeptide antibodies or a pharmaceutically acceptable salt thereof for parenteral administration. In particular, stable liquid formulations and compositions comprising vancomycin or a pharmaceutically acceptable salt thereof, N-acetyl-methionine and one or more pharmaceutically acceptable excipients. The invention also relates to a process of preparing such compositions and methods and uses thereof.

Abstract: The invention relates to formulations and compositions comprising one or more glycopeptide antibodies or a pharmaceutically acceptable salt thereof for parenteral administration. In particular, stable liquid formulations and compositions comprising vancomycin or a pharmaceutically acceptable salt thereof, N-acetyl-methionine and one or more pharmaceutically acceptable excipients. The invention also relates to a process of preparing such compositions and methods and uses thereof.

Abstract: Disclosed herein are compositions comprising tobramycin or a tobramycin derivative that exhibit improvements in permeation of corneal cells, retention in corneal cells, or both. Such compositions can comprise tobramycin or tobramycin derivative(s) complexed to an agent which facilitates improved permeation of corneal cells, retention in corneal cells, or both. The invention also relates to a process of preparing such compositions.

Abstract: Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a triamcinolone compound. In aspects, the compositions are stable suspensions, which maintain physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent that provides both functions. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g.

Abstract: The present invention relates to liquid formulations of epinephrine or a pharmaceutically acceptable salt thereof intended for parenteral administration. In particular, the invention provides liquid formulations comprising levorotatory-epinephrine (l-epinephrine) in a concentration of about 0.5 to about 1.5 mg/mL and at least one antioxidant. The antioxidant is selected from the group consisting of ascorbic acid, sodium ascorbate, monothioglycerol, vitamin-A, vitamin-B1, vitamin-B2, vitamin-B6, vitamin-E, butylated hydroxy toluene, butylated hydroxy anisole and propyl gallate, alone or in a combination. The formulations prepared by using the current invention exhibit good physical and chemical stability.

Abstract: The present invention relates to liquid formulations of levothyroxine or a pharmaceutically acceptable salt thereof intended for parenteral administration, wherein the formulations are devoid of tromethamine. In particular, the invention provides a stable ready-to-use liquid formulation of levothyroxine or a pharmaceutically acceptable salt thereof intended for parenteral administration, wherein the formulation is devoid of tromethamine. The formulations prepared by using the current invention exhibit good physical and chemical stability.

Abstract: The present invention relates to an ophthalmic composition comprising cetirizine and one or more pharmaceutically acceptable excipients, wherein said composition is free of benzalkonium chloride and/or dibasic sodium phosphate. The invention particularly relates to a 0.24% cetirizine ophthalmic composition, wherein said composition is free of benzalkonium chloride and/or dibasic sodium phosphate. Further, the invention may also provide a process of preparing such composition and their use for treating allergic conjunctivitis and/or allergic rhinoconjunctivitis.

Abstract: The present invention relates to a process for preparation of an insoluble corticosteroid and a soluble corticosteroid composition by moist heat sterilization and homogenization. In particular, the invention relates to a process for the preparation of a sterilized suspension of betamethasone acetate and betamethasone sodium phosphate, wherein the process comprises sterilizing a slurry of the betamethasone acetate by moist heat sterilization or autoclaving in about 30% to about 70% of water to a temperature of about 115° C. to about 128° C. for about 15 minutes to about 60 minutes under nitrogen atmosphere. The suspensions prepared by using the current invention exhibited good physical and chemical stability. Compositions related thereto are also disclosed.

Abstract: The present invention relates to a process for preparation of a water-insoluble steroid composition by moist heat sterilization. The invention particularly relates to a process for preparation of a water-insoluble steroid composition comprising moist heat sterilization or autoclaving of an aqueous slurry of methylprednisolone acetate in the presence of a specified quantity of polysorbate. The suspensions prepared by using the current invention exhibited good physical and chemical stability. Compositions related thereto are also disclosed.

Abstract: The present invention relates to a process for preparation of a water-insoluble steroid composition by moist heat sterilization. Particularly, the invention relates to a process for preparation of a water-insoluble steroid composition comprising moist heat sterilization of an aqueous slurry of the steroid triamcinolone acetonide in the presence of benzyl alcohol, sodium chloride and sodium carboxymethylcellulose under a nitrogen atmosphere. The suspensions prepared by using the current invention exhibited good physical and chemical stability. Compositions related thereto are also disclosed.

Abstract: The present invention provides an emulsion composition comprising aprepitant for treatment of emesis. Particularly, the invention is a ready-to-use emulsion compositions comprising aprepitant and medium chain triglycerides for administration by intravenous infusion, wherein the emulsion composition is also free of ethanol. Further, the invention also provides processes of preparing such compositions and their use for the prevention and control of acute and delayed chemotherapy-induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.

Abstract: An aqueous ophthalmic solution containing a relatively high concentration of olopatadine in solubilized form is provided. The solution comprises a combination of at least two non-ionic surfactants and is essentially devoid of cyclodextrins. The solution is useful for providing enhanced relief from symptoms of ocular allergic disorders (e.g. conjunctivitis).